Oncology Central

Bristol-Myers hooks immuno-oncology drug in billion dollar deal: industry news round up


Bristol-Myers Squibb hooks the next big immuno-oncology drug in record $3.6 billion deal with Nektar

Nektar Therapeutics has made a record, multi­bil­lion-dol­lar part­ner­ship deal with Bris­tol-Myers Squibb (BMS) for a mi­nor­ity share of its early-stage im­muno-on­col­ogy drug NKTR-214.

The deal provides BMS with an exclusive development period to pursue a broad new combo development program covering 20 indications involving nine tumors, matching ‘214 with BMS’s two existing immuno-oncology leaders – PD-1 (Opdivo®) and CTLA-4 (Yervoy®).

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.